| Carl-yves Durand, | |
|
8 Rillstone Ct, Freehold, NJ 07728-8574 | |
| (732) 939-5085 | |
| Not Available |
| Full Name | Carl-yves Durand |
|---|---|
| Gender | Male |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 8 Rillstone Ct, Freehold, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205287059 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | DN25617 (Florida) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Carl-yves Durand, 5380 Donald Ross Rd Ste 100, Palm Beach Gardens, FL 33418-7282 Ph: (732) 939-5085 | Carl-yves Durand, 8 Rillstone Ct, Freehold, NJ 07728-8574 Ph: (732) 939-5085 |
News Archive
Administering a substance found in the cannabis plant can help the body's natural protective system alleviate an allergic skin disease (allergic contact dermatitis), an international group of researchers from Germany, Israel, Italy, Switzerland and the U.S. has found.
One year post-surgery, patients who underwent Descemet's stripping automated endothelial keratoplasty (DSAEK) experienced greater cell loss overall compared to those who underwent penetrating keratoplasty (PKP), according to a new analysis of data collected from the Cornea Donor Study (CDS) Investigator Group's 2008 Specular Microscopy Ancillary Study (SMAS). However, the study, published in the March issue of Ophthalmology, showed that cell loss in DSAEK patients plateaued more quickly than in those who underwent PKP.
GetWellNetwork, Inc., the leading provider of Interactive Patient Care (IPC) solutions, today announced that major hospitals and healthcare providers selected its award-winning IPC solutions to improve patient engagement and quality. Additionally, hospitals already using GetWellNetwork's IPC solutions chose to expand and renew their projects to continue reaping performance improvements and affecting positive outcomes for their patients.
Medivir AB (STO:MVIR-B) (OMX: MVIR), announces the initiation of a phase IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.
NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the launch of its early access program for a unique new solution that detects copy number variation in human genomic samples. The program was announced in conjunction with the company's participation in the European Human Genetics Conference in Gothenburg, Sweden.
› Verified 2 days ago